B. Rosbrook

发表

Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.

G. Wilding, B. Rini, G. Hudes, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone

J. Maurel, H. Wasan, J. Spano, 2009, British Journal of Cancer.

Reducing tobacco consumption in California: Proposition 99 seems to work.

E. Gilpin, J. Pierce, C. Berry, 1991, JAMA.

Tobacco Use in California An Evaluation of the Tobacco Contol Program, 1989-1993

W. Choi, C. Berry, B. Rosbrook, 1994 .

Impact of the American Stop Smoking Intervention Study on cigarette consumption.

E. Gilpin, J. Pierce, L. Wun, 1997, Tobacco control.

Baseline patient-reported kidney cancer-specific symptoms as an indicator for median survival in sorafenib-refractory metastatic renal cell carcinoma

B. Rini, J. Cappelleri, P. Bycott, 2011, Journal of cancer survivorship.

Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study.

C. Tournigand, Z. Wainberg, J. Bendell, 2013, Clinical colorectal cancer.

ATLAS trial of adjuvant axitinib in patients with renal cell carcinoma: subgroup analyses with focus on axitinib dosing and racial groups

D. Quinn, C. Ng, E. Grande, 2021, ESMO open.

Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial

R. Motzer, B. Rini, D. Quinn, 2014, Targeted Oncology.

Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses.

G. Haas, A. Villers, A. Armstrong, 2020, The Journal of urology.

Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial

M. Casey, H. Miyake, V. Master, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Updated Efficacy and Safety Outcomes for Patients with Well-Differentiated Pancreatic Neuroendocrine Tumors Treated with Sunitinib

E. Raymond, N. Fazio, M. Kulke, 2021, Targeted Oncology.

Sunitinib in patients with pancreatic neuroendocrine tumors: update of safety data.

E. Raymond, J. Valle, I. Borbath, 2019, Future oncology.

Pharmacogenomic analyses of sunitinib in patients with pancreatic neuroendocrine tumors.

E. Raymond, N. Fazio, A. Croitoru, 2019, Future oncology.

Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial.

F. Saad, A. Armstrong, C. Higano, 2020, European urology.

Long-Term Safety With Axitinib in Previously Treated Patients With Metastatic Renal Cell Carcinoma.

R. Motzer, B. Rini, B. Escudier, 2015, Clinical genitourinary cancer.

2509 Overall survival analysis from a randomised phase III trial of axitini vs sorafenib as first-line therapy in patients with metastatic renal cell carcinoma

N. Vogelzang, Thomas E. Hutson, O. Lipatov, 2015 .

Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial.

T. Choueiri, M. Atkins, M. Fishman, 2018, The Lancet. Oncology.

Association of diastolic blood pressure (dBP) ≥ 90 mmHg with overall survival (OS) in patients treated with axitinib (AG- 013736).

B. Rini, J. Schiller, E. Cohen, 2008 .

The impact of enzalutamide on quality of life in men with metastatic hormone‐sensitive prostate cancer based on prior therapy, risk, and symptom subgroups

G. Haas, A. Villers, A. Armstrong, 2022, The Prostate.

Cigarette smoking behavior and beliefs of Hispanics in California.

L. Palinkas, J. Pierce, B. Rosbrook, 1993, American journal of preventive medicine.

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial

R. Motzer, M. Gore, R. Motzer, 2011, The Lancet.

Time to Resolution of Axitinib-Related Adverse Events After Treatment Interruption in Patients With Advanced Renal Cell Carcinoma.

T. Choueiri, M. Atkins, B. Rini, 2021, Clinical genitourinary cancer.

Is Axitinib Still a Valid Option for mRCC in the Second-Line Setting? Prognostic Factor Analyses From the AXIS Trial.

A. Bamias, S. Bracarda, M. Staehler, 2019, Clinical genitourinary cancer.

Axitinib Versus Sorafenib in First‐Line Metastatic Renal Cell Carcinoma: Overall Survival From a Randomized Phase III Trial

N. Vogelzang, Thomas E. Hutson, O. Lipatov, 2017, Clinical genitourinary cancer.

Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): Results of phase III AXIS trial.

R. Motzer, B. Rini, C. Szczylik, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sunitinib in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to International Metastatic Renal Cell Carcinoma Database Consortium Risk Group

R. Figlin, R. Motzer, B. Rini, 2018, Clinical genitourinary cancer.

Sequential axitinib (AG-013736) therapy of patients (pts) with metastatic clear cell renal cell cancer (RCC) refractory to sunitinib and sorafenib, cytokines and sorafenib, or sorafenib alone

G. Wilding, B. Rini, G. Hudes, 2008 .

Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk

G. Haas, A. Villers, A. Armstrong, 2021, Prostate Cancer and Prostatic Diseases.

1231 A phase I study of axitinib (AG-013736) combined with paclitaxel/carboplatin (P/C), gemcitabine/cisplatin (Gem/Cis) or pemetrexed/cisplatin (Pem/Cis) in patients (pts) with solid tumours, including advanced non-small cell lung cancer (NSCLC)

R. Cohen, M. Tortorici, A. Olszanski, 2009 .

Axitinib or bevacizumab (bev) plus FOLFOX or FOLFIRI as second-line therapy in patients (pts) with metastatic colorectal cancer (mCRC).

C. Tournigand, J. Bendell, A. Ricart, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Overall Survival Analysis From a Randomized Phase II Study of Axitinib With or Without Dose Titration in First-Line Metastatic Renal Cell Carcinoma.

E. Jonasch, M. Fishman, B. Melichar, 2016, Clinical genitourinary cancer.

Phase III study of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): The ARCHES trial.

A. Villers, A. Armstrong, D. Petrylak, 2019, Journal of Clinical Oncology.

Axitinib inhibition of [18F] fluorothymidine (FLT) uptake in patients (pts) with colorectal cancer (CRC): Implications for cytotoxic chemotherapy combinations.

C. Hoh, H. Burris, J. Infante, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Addiction versus stages of change models in predicting smoking cessation.

E. Gilpin, A. Farkas, J. Pierce, 1996, Addiction.

Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer

G. Haas, A. Villers, A. Armstrong, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.

R. Motzer, M. Gore, M. Michaelson, 2013, The Lancet. Oncology.

Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid Tumors

B. Rini, J. Schiller, E. Cohen, 2011, Clinical Cancer Research.

ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer

A. Villers, A. Armstrong, D. Petrylak, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

LBA25 Final overall survival (OS) analysis from ARCHES: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) + androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC)

G. Haas, A. Villers, D. Petrylak, 2021, Annals of Oncology.

Genotype Correlations With Blood Pressure and Efficacy From a Randomized Phase III Trial of Second-Line Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma.

R. Motzer, B. Rini, Xin Huang, 2015, Clinical genitourinary cancer.

A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study design

G. Haas, M. Gleave, S. Freedland, 2021, BMJ Open.

Does tobacco advertising target young people to start smoking? Evidence from California.

D Shopland, E. Gilpin, J. Pierce, 1991, JAMA.

Phase 3 study of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (MHSPC): The ARCHES trial

A. Villers, A. Armstrong, D. Petrylak, 2019, European urology. Supplement.

Enzalutamide with androgen deprivation therapy in Japanese men with metastatic hormone‐sensitive prostate cancer: A subgroup analysis of the phase III ARCHES study

A. Armstrong, A. Yokomizo, A. Stenzl, 2021, International journal of urology : official journal of the Japanese Urological Association.

Lower levels of cigarette consumption found in smoke-free workplaces in California.

S A Glantz, T J Woodruff, S. Glantz, 1993, Archives of internal medicine.

Has the California tobacco control program reduced smoking?

E. Gilpin, A. Farkas, M. White, 1998, JAMA.

Telephone counseling for smoking cessation: effects of single-session and multiple-session interventions.

M. Balabanis, J. Pierce, Shu-Hong Zhu, 1996, Journal of consulting and clinical psychology.

The demographics of help-seeking for smoking cessation in California and the role of the California Smokers’ Helpline

Elizabeth A. Gilpin, Georgia Robins Sadler, Shu-Hong Zhu, 1995, Tobacco Control.

Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.

N. Vogelzang, V. Lesovoy, Thomas E. Hutson, 2013, The Lancet. Oncology.

Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma

T. Choueiri, M. Atkins, M. Fishman, 2020, Clinical Cancer Research.

Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial

R. Motzer, M. Michaelson, B. Rini, 2014, British Journal of Cancer.

Multicenter, Phase II Study of Axitinib, a Selective Second-Generation Inhibitor of Vascular Endothelial Growth Factor Receptors 1, 2, and 3, in Patients with Metastatic Melanoma

D. McDermott, J. Lutzky, D. Shalinsky, 2011, Clinical Cancer Research.

Public objections to environmental tobacco smoke.

J. Pierce, J. Elder, W. Choi, 1992, Preventive medicine.

Smoking cessation with and without assistance: a population-based analysis.

J. Pierce, T. Melcer, Shu-Hong Zhu, 2000, American journal of preventive medicine.

Evidence of real-world effectiveness of a telephone quitline for smokers.

Shu-Hong Zhu, G. Tedeschi, C. Anderson, 2002, The New England journal of medicine.

Axitinib versus sorafenib as first‑line therapy in patients with metastatic renal cell carcinoma (mRCC).

P. Bycott, N. Vogelzang, J. Tarazi, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cancer Therapy : Clinical Multicenter , Phase II Study of Axitinib , a Selective Second-Generation Inhibitor of Vascular Endothelial Growth Factor Receptors 1 , 2 , and 3 , in Patients with Metastatic Melanoma

D. McDermott, J. Lutzky, D. Shalinsky, 2011 .

Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours

R. Herbst, R. Cohen, J. de Castro Carpeno, 2012, British Journal of Cancer.

Does advertising promote smokeless tobacco use among adolescent boys? Evidence from California

A. Farkas, J. Pierce, J. Elder, 1995, Tobacco Control.

Telephone counseling as adjuvant treatment for nicotine replacement therapy in a "real-world" setting.

C M Anderson, B Rosbrook, S H Zhu, 2000, Preventive medicine.

Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer.

H. Rugo, A. Stopeck, P. Bycott, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Improved survival for frail elderly inpatients on a geriatric evaluation unit (GEU): who benefits?

L. Rubenstein, R. Kane, R. Kane, 1988, Journal of clinical epidemiology.

Are adolescents receptive to current sales promotion practices of the tobacco industry?

E. Gilpin, J. Pierce, E A Gilpin, 1997, Preventive medicine.

Is stage-of-change a useful measure of the likelihood of smoking cessation?

E. Gilpin, A. Farkas, J. Pierce, 1996, Annals of behavioral medicine : a publication of the Society of Behavioral Medicine.

Phase Ib dose-finding study of axitinib plus pembrolizumab in treatment-naïve patients with advanced renal cell carcinoma

T. Choueiri, M. Atkins, E. Plimack, 2015, Journal of Immunotherapy for Cancer.

Genitourinary tumors, non-prostate

S. J. Park, I. Tannock, S. Groshen, 2012 .

Efficacy of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) in men with de novo (M1) metastatic hormone-sensitive prostate cancer (mHSPC) versus progression to mHSPC (M0): Post hoc analysis of the phase III ARCHES trial.

G. Haas, A. Villers, A. Armstrong, 2021 .

First-line axitinib versus sorafenib in Asian patients with metastatic renal cell carcinoma: exploratory subgroup analyses of Phase III data.

Ying Cheng, F. Bi, X. Ren, 2019, Future oncology.

The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES.

G. Haas, A. Villers, B. Alekseev, 2023, European urology.

A randomized phase II study comparing mFOLFOX-6 combined with axitinib or bevacizumab or both in patients with metastatic colorectal cancer (mCRC).

J. Hamm, J. Infante, W. Edenfield, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours

R. Herbst, R. Cohen, M. Tortorici, 2012, British Journal of Cancer.

Long-term Duration of First-Line Axitinib Treatment in Advanced Renal Cell Carcinoma

E. Jonasch, M. Fishman, M. Michaelson, 2017, Targeted Oncology.

Axitinib in combination with pembrolizumab in patients (pts) with advanced renal cell carcinoma (aRCC): Preliminary safety and efficacy results

T. Choueiri, M. Atkins, M. Fishman, 2016 .

Phase Ib study of axitinib in combination with crizotinib in patients with advanced solid tumors.

M. Michaelson, J. Martini, D. Shepard, 2014 .

Axitinib and/or bevacizumab with modified FOLFOX‐6 as first‐line therapy for metastatic colorectal cancer: A randomized phase 2 study

J. Hamm, J. Infante, W. Edenfield, 2013, Cancer.

Patient-reported outcomes (PROs) in a phase III AXIS trial of axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC).

R. Motzer, D. Cella, B. Rini, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial

R. Motzer, D. Cella, B. Rini, 2013, British Journal of Cancer.

Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours

E. Raymond, J. Šufliarský, P. Ruff, 2018, Neuroendocrinology.

Projecting international lung cancer mortality rates: first approximations with tobacco-consumption data.

J. Pierce, B. Rosbrook, L. Thurmond, 1992, Journal of the National Cancer Institute. Monographs.

Sample size considerations when groups are the appropriate unit of analysis.

Eric Miller, Georgia Robins Sadler, Celine Marie Ko, 2007, Applied nursing research : ANR.

A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors

T. Powles, N. Agarwal, M. Michaelson, 2019, The oncologist.

Commentary on "Comparative effectiveness of axitinib vs. sorafenib in advanced renal cell carcinoma (AXIS): A randomized phase

D. Cella, C. Szczylik, B. Escudier, 2012 .

Intermittent dosing of axitinib combined with chemotherapy is supported by 18FLT-PET in gastrointestinal tumours

C. Hoh, J. Bendell, H. Burris, 2014, British Journal of Cancer.

Multicenter, Phase II Study of Axitinib, a Selective Second-Generation Inhibitor of Vascular Endothelial Growth Factor Receptors 1, 2, and 3, in Patients with Metastatic Melanoma

D. McDermott, J. Lutzky, D. Shalinsky, 2011, Clinical Cancer Research.

Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid Tumors

B. Rini, J. Schiller, E. Cohen, 2011, Clinical Cancer Research.

Evidence of real-world effectiveness of a telephone quitline for smokers.

Shu-Hong Zhu, G. Tedeschi, B. Rosbrook, 2002, The New England journal of medicine.

Plain language summary looking at how long side effects last after treatment with axitinib is stopped in people with advanced renal cell carcinoma?

T. Choueiri, M. Atkins, B. Rini, 2023, Future oncology.

The efficacy and safety of sunitinib in patients with advanced well-differentiated pancreatic neuroendocrine tumors.

E. Raymond, Jianming Xu, P. Ruff, 2017 .

Axitinib vs Sorafenib for Advanced Renal Cell Carcinoma: Phase III Overall Survival Results and Analysis of Prognostic Factors

R. Motzer, B. Rini, B. Escudier, 2012 .

Phase III AXIS trial for second-line metastatic renal cell carcinoma (mRCC): Effect of prior first-line treatment duration and axitinib dose titration on axitinib efficacy.

R. Motzer, M. Gore, M. Michaelson, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

276PFirst-line axitinib versus sorafenib in Asian patients with metastatic renal cell carcinoma (mRCC): Subgroup analysis of data from a phase III trial

F. Bi, Y. Cheng, X. Ren, 2017 .